In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

CAT, Genzyme to develop anti-TGF-beta MAbs

Executive Summary

Genzyme General has licensed exclusive worldwide rights to Cambridge Antibody Technology's fully human anti-TGF-beta monoclonal antibodies for all therapeutic areas, excluding ophthalmology. The partners will co-develop antibodies, primarily for scleroderma treatment, share profits, marketing efforts, and jointly fund R&D.
Deal Industry
  • Biotechnology
    • Large Molecule
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Equity
    • R+D and Marketing-Licensing
    • Intra-Biotech Deal

Related Companies

Advertisement
UsernamePublicRestriction

Register